– USA, NC – GeneCentric Therapeutics, a company making precision medicine more precise through RNA-based diagnostics, today announced the appointment of Dr. Prasanth Reddy (MD, MPH, FACP) and Don Hardison to its Board as Independent Directors.
Concurrently, Ellen Lubman will resign from the Board.
About Dr. Prasanth Reddy
Dr. Prasanth Reddy is triple board-certified in internal medicine, medical oncology, and hematology and practiced medicine and served in leadership positions for more than 10 years in various clinical settings including academia, private practice, and managed care. Most recently, he served as SVP of Global Enterprise Oncology Head at Labcorp and VP of Medical Affairs at Foundation Medicine. Before Foundation Medicine, Dr. Reddy worked as a national leader developing oncology service line treatment pathways at the Adventist Health System.
About Don Hardison
Don Hardison has over 40 years of executive leadership experience in emerging and Fortune 500 diagnostics, biotechnology, and life sciences companies, including President and CEO of Exact Sciences, EVP and COO of Labcorp, and most recently, President and CEO of Biotheranostics. He currently serves as a board member of several life sciences companies including MDxHealth, BioPorto, Cytek Biosciences, Arima Genomics, Geneoscopy, and Decode Health.
About GeneCentric
GeneCentric Therapeutics, Inc. is an RNA-based genomic solutions provider based in Durham, North Carolina. The company designed its technologies to parse the complexity of tumor and immune biology using its RNA-based Tumor and Immune Micro-Environment Explorer platform to discover and develop signatures of responder populations to oncology therapeutics. GeneCentric commercializes its technology through strategic collaborations with pharmaceutical, biotechnology, and diagnostics companies in applications throughout preclinical testing, clinical drug development, and commercialization lifecycle phases.
For more information: https://genecentric.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
